All In Biotech

Drug Trial Radar · NCT07647783

A Single and Multiple Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SYH2072 Tablets

A Phase I, Single-Center, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Clinical Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SYH2072 Tablets in Healthy Participants

Last checked: Nov 19, 2026Latest source record: Jun 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 112 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

112

Planned (sponsor's estimate)

Start

Jan 15, 2026

Primary completion

Feb 1, 2027

Study completion Apr 1, 2027

Sponsor

Sponsor type
Industry
First posted
Jun 15, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a first-in-human study to evaluate the safety, tolerability, PK, and PD characteristics of SYH2072 Tablets after single and multiple oral doses in healthy participants.

Conditions

  • Healthy Participants

Interventions

  • SYH2072 TabletsDrug

    SYH2072 tablets will be administered as a single or multiple oral doses.

  • SYH2072 PlaceboDrug

    SYH2072 placebo tablets will be administered as a single or multiple oral doses.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The rate of Adverse eventsTime frame: Through study completion, an average of 8 months
  2. The rate of normality or abnormality of electrocardiogramTime frame: Through study completion, an average of 8 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Anzhen Hospital, Capital Medical University

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.